The Tealwood Asset Management Inc. decides to keep it stake in United Therapeutics Corp. (UTHR) to the level of $2,459,000

The Tealwood Asset Management Inc. decides to keep it stake in United Therapeutics Corp. (UTHR) to the level of $2,459,000

Tealwood Asset Management Inc. boosted its position in United Therapeutics Corp. (NASDAQ:UTHR) by 2.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,215 shares of the biotechnology company’s stock after buying an additional 540 shares during the period. Tealwood Asset Management Inc.’s holdings in United Therapeutics Corp. were worth $2,459,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in UTHR. Daiwa Securities Group Inc. increased its stake in shares of United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock worth $111,000 after buying an additional 150 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock worth $128,000 after buying an additional 190 shares in the last quarter. Eqis Capital Management Inc. purchased a new stake in shares of United Therapeutics Corp. during the second quarter worth about $254,000. Creative Planning increased its stake in shares of United Therapeutics Corp. by 330.4% in the second quarter. Creative Planning now owns 2,410 shares of the biotechnology company’s stock worth $255,000 after buying an additional 1,850 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. increased its stake in shares of United Therapeutics Corp. by 10.9% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,540 shares of the biotechnology company’s stock worth $283,000 after buying an additional 250 shares in the last quarter.

United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.60% during midday trading on Friday, hitting $116.89. 545,831 shares of the stock traded hands. United Therapeutics Corp. has a one year low of $97.52 and a one year high of $164.04. The company’s 50-day moving average is $121.92 and its 200-day moving average is $115.96. The company has a market cap of $5.08 billion, a PE ratio of 5.65 and a beta of 1.42.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.22 by $1.33. The business had revenue of $412.60 million for the quarter, compared to the consensus estimate of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.55 earnings per share. Equities research analysts expect that United Therapeutics Corp. will post $15.82 EPS for the current fiscal year.

Several research firms recently weighed in on UTHR. Cowen and Company reiterated a “buy” rating and issued a $144.00 target price on shares of United Therapeutics Corp. in a report on Friday, September 23rd. Zacks Investment Research upgraded shares of United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 target price for the company in a report on Tuesday, July 26th. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a report on Friday, July 29th. Jefferies Group reiterated a “hold” rating and issued a $120.00 target price on shares of United Therapeutics Corp. in a report on Friday, July 29th. Finally, Argus reiterated a “hold” rating on shares of United Therapeutics Corp. in a report on Tuesday, August 23rd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. United Therapeutics Corp. has an average rating of “Hold” and an average target price of $137.09.

In other news, Director Christopher Patusky sold 5,000 shares of the stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $122.73, for a total value of $613,650.00. Following the completion of the sale, the director now owns 5,000 shares of the company’s stock, valued at $613,650. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,271 shares of the stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $117.05, for a total transaction of $148,770.55. Following the completion of the sale, the chief executive officer now directly owns 1,411 shares of the company’s stock, valued at approximately $165,157.55. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company’s stock.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Related posts

Leave a Comment